Signaturefd, LLC Summit Therapeutics Inc. Transaction History

Signaturefd, LLC

$5.2 Billion
Q3 2024

A detailed history of Signaturefd, LLC transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Signaturefd, LLC holds 21 shares of SMMT stock, worth $493. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Previous 21 -0.0%

Holding current value

$493

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 29, 2024	SELL	$2.39 - $10.92 $246 - $1,124	-103 Reduced 83.06%	21 $0
Q1 2024 May 03, 2024	BUY	$2.55 - $5.07 $262 - $522	103 Added 490.48%	124 $0
Q4 2023 Jan 31, 2024	SELL	$1.67 - $2.83 $4,323 - $7,326	-2,589 Reduced 99.2%	21 $0
Q3 2023 Nov 03, 2023	BUY	$1.54 - $2.42 $3,369 - $5,294	2,188 Added 518.48%	2,610 $4,000
Q2 2023 Aug 01, 2023	SELL	$1.32 - $2.81 $3,772 - $8,030	-2,858 Reduced 87.13%	422 $1,000
Q1 2023 Apr 28, 2023	BUY	$1.38 - $5.41 $4,465 - $17,506	3,236 Added 7354.55%	3,280 $5,000
Q4 2022 Jan 27, 2023	BUY	$0.68 - $5.31 $29 - $233	44 New	44 $0
Q1 2022 May 02, 2022	SELL	$2.0 - $3.45 $398 - $686	-199 Closed	0 $0
Q4 2021 Jan 25, 2022	SELL	$2.45 - $5.64 $2,352 - $5,414	-960 Reduced 82.83%	199 $1,000
Q3 2021 Oct 28, 2021	SELL	$4.83 - $8.27 $1,970 - $3,374	-408 Reduced 26.04%	1,159 $6,000
Q2 2021 Jul 26, 2021	BUY	$5.15 - $8.46 $3,491 - $5,735	678 Added 76.27%	1,567 $12,000
Q1 2021 Apr 30, 2021	BUY	$5.17 - $11.19 $2,497 - $5,404	483 Added 118.97%	889 $5,000
Q4 2020 Feb 11, 2021	BUY	$3.25 - $6.0 $1,319 - $2,436	406 New	406 $2,000

Others Institutions Holding SMMT

# of Institutions

199

Shares Held

76M

Call Options Held

2.01M

Put Options Held

2.84M

View Full List

About Summit Therapeutics Inc.

Ticker SMMT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 201,215,008
Market Cap $4.73B
Description
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...

More about SMMT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Signaturefd, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Signaturefd, LLC with notifications on news.

Account